UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
i March 19, 2020
i CANTEL MEDICAL CORP
(Exact name of registrant as specified in its charter)
|
i Delaware
|
|
i 22-1760285
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Identification
Number)
|
i 150 Clove Road, i Little Falls, i New
Jersey
|
|
i 07424
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: ( i 973) i 890-7220
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
i ☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
i ☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
i ☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
i ☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
| |
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
| |
i Common Stock
|
|
i CMD
|
|
i New York Stock Exchange
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
| Item 7.01 |
Regulation FD Disclosure.
|
On
March 19, 2020, representatives of
the Company began making presentations to investors using slides containing the information attached to this Current Report on Form 8-K as
Exhibit 99.1 (the
“Investor Presentation”) and
incorporated herein by reference.
The Company expects to use the Investor Presentation, in whole or in part, and possibly with modifications, in connection with presentations to investors, analysts and
others during the fiscal year ending
July 31, 2020.
By filing this Current Report on Form 8-K and furnishing the information contained herein,
the Company makes no admission as to the materiality of any information in this report that
is required to be disclosed solely by reason of Regulation FD.
The information contained in the Investor Presentation is summary information that is intended to be considered in the context of
the Company's Securities and Exchange Commission
(
“SEC”) filings and other public announcements that
the Company may make, by
press release or otherwise, from time to time.
The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although
it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through
press releases or through other public disclosure.
| Item 9.01 |
Financial Statements, Pro-Forma Financial Information and Exhibits.
|
(d) Exhibits
|
104.1
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
CANTEL MEDICAL CORP.
|
| |
|
| |
By:
|
|
| |
|
|
| |
|
President and Chief Executive Officer
|
| |
|
|
|
|
|
|
